Short Interest in Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Drops By 37.4%

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) saw a significant decline in short interest in December. As of December 31st, there was short interest totaling 6,009 shares, a decline of 37.4% from the December 15th total of 9,599 shares. Currently, 0.6% of the company’s stock are short sold. Based on an average daily volume of 2,678 shares, the days-to-cover ratio is currently 2.2 days. Based on an average daily volume of 2,678 shares, the days-to-cover ratio is currently 2.2 days. Currently, 0.6% of the company’s stock are short sold.

Addex Therapeutics Stock Down 1.5%

Shares of NASDAQ ADXN opened at $7.98 on Friday. Addex Therapeutics has a fifty-two week low of $6.51 and a fifty-two week high of $12.05. The business has a 50 day moving average price of $8.06 and a two-hundred day moving average price of $8.53. The firm has a market cap of $9.82 million, a PE ratio of -1.39 and a beta of 1.49.

Addex Therapeutics (NASDAQ:ADXN) last released its earnings results on Thursday, December 4th. The company reported ($1.51) EPS for the quarter. The firm had revenue of $0.04 million during the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Addex Therapeutics in a research note on Friday, January 9th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

About Addex Therapeutics

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.